188 related articles for article (PubMed ID: 35617966)
21. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.
Boesen MS; Jensen PEH; Born AP; Magyari M; Nilsson AC; Hoei-Hansen C; Blinkenberg M; Sellebjerg F
Mult Scler Relat Disord; 2019 Aug; 33():162-167. PubMed ID: 31276927
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
Mariano R; Messina S; Kumar K; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2019 Oct; 2(10):e1912732. PubMed ID: 31596489
[TBL] [Abstract][Full Text] [Related]
23. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
24. Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
Reindl M; Waters P
Nat Rev Neurol; 2019 Feb; 15(2):89-102. PubMed ID: 30559466
[TBL] [Abstract][Full Text] [Related]
25. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
26. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
27. MOG antibody-related disorders: common features and uncommon presentations.
Cobo-Calvo Á; Ruiz A; D'Indy H; Poulat AL; Carneiro M; Philippe N; Durand-Dubief F; Deiva K; Vukusic S; Desportes V; Marignier R
J Neurol; 2017 Sep; 264(9):1945-1955. PubMed ID: 28770374
[TBL] [Abstract][Full Text] [Related]
28. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
[TBL] [Abstract][Full Text] [Related]
29. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.
Peschl P; Bradl M; Höftberger R; Berger T; Reindl M
Front Immunol; 2017; 8():529. PubMed ID: 28533781
[TBL] [Abstract][Full Text] [Related]
30. Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease in Korean Children.
Yoo IH; Kim W; Shim Y; Choi SA; Kim SY; Kim H; Lim BC; Hwang H; Choi J; Kim KJ; Kim Y; Hyun JW; Kim SH; Choi K; Kim HJ; Chae JH
J Clin Neurol; 2020 Jul; 16(3):461-469. PubMed ID: 32657068
[TBL] [Abstract][Full Text] [Related]
31. Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective.
Chaudhuri J; Biswas T; Ganguly G; Datta S; Pandit A; Biswas A
Acta Neurol Belg; 2021 Aug; 121(4):927-931. PubMed ID: 32314270
[TBL] [Abstract][Full Text] [Related]
32. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
33. [Anti-Myelin Oligodendrocyte Glycoprotein Antibodies in Paediatric Patients with Optic Neuritis].
Tegetmeyer H; Merkenschlager A
Klin Monbl Augenheilkd; 2017 Oct; 234(10):1243-1249. PubMed ID: 29025172
[No Abstract] [Full Text] [Related]
34. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
Front Immunol; 2020; 11():1188. PubMed ID: 32625206
[TBL] [Abstract][Full Text] [Related]
35. Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania.
Sakalauskaitė-Juodeikienė E; Armalienė G; Kizlaitienė R; Bagdonaitė L; Giedraitienė N; Mickevičienė D; Rastenytė D; Kaubrys G; Jatužis D
Brain Behav; 2018 Nov; 8(11):e01129. PubMed ID: 30284401
[TBL] [Abstract][Full Text] [Related]
36. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
37. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.
Armangue T; Olivé-Cirera G; Martínez-Hernandez E; Sepulveda M; Ruiz-Garcia R; Muñoz-Batista M; Ariño H; González-Álvarez V; Felipe-Rucián A; Jesús Martínez-González M; Cantarín-Extremera V; Concepción Miranda-Herrero M; Monge-Galindo L; Tomás-Vila M; Miravet E; Málaga I; Arrambide G; Auger C; Tintoré M; Montalban X; Vanderver A; Graus F; Saiz A; Dalmau J;
Lancet Neurol; 2020 Mar; 19(3):234-246. PubMed ID: 32057303
[TBL] [Abstract][Full Text] [Related]
38. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
[TBL] [Abstract][Full Text] [Related]
39. Anti-Argonaute antibodies as a potential biomarker in NMOSD.
Carta S; Le Duy D; Rogemond V; Derache N; Chaumont H; Fromont A; Cabasson S; Boudot de la Motte M; Honnorat J; Marignier R
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):738-741. PubMed ID: 36810322
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Prognostic Analysis of Autoantibody-Associated CNS Demyelinating Disorders in Children in Southwest China.
Li Z; Sun H; Fan X; Yuan P; Jiang Y; Wu P; Zhong M; Ma J; Jiang L; Li X
Front Neurol; 2021; 12():642664. PubMed ID: 33841310
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
